

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016
Email: shreeganeshbiotechindia@gmail.com Website: www.shreeganeshbiotech.com

Date: 04.02.2025

To,
Listing Department,
BSE Limited, .
P J Tower, Dalal Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock
Exchange of India Limited
Vibgyor Towers, 4th floor,
Plot Noe 62, Opp. Trident
Hotel Bandra Kurla Complex,
Bandra (E)
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221


Scrip Code-SHREEGANES

Sub. : Integrated Filing (Financial) for the quarter and Nine-month ended 31st December, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, please find attached herewith the Integrated Filing (Financial) for the Quarter and Nine-month ended 31st December, 2024.:

A	Financial Results	Attached as Annexure-1
B	Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	Attached as Annexure-II
C	Format for disclosing outstanding default on loans and debt securities	Not Applicable
D	Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)	Not Applicable for this quarter
E	Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (Applicable only for annual filing i.e., 4th quarter)	Not Applicable for this quarter

FOR SHREE GANESH BIO-TECH (INDIA)LIMITED



Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindia@gmail.com

Statement of Standalone Financial Results for the quarter ended on December 31, 2024

(₹ In Lakh except per share data)


Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
A Date of start of reporting period	01-10-2024	01-07-2024	01-10-2023	01-04-2024	01-04-2023	01-04-2023
B Date of end of reporting period	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
C Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
I Revenue From Operations						
Net sales or Revenue from Operations	1,441.18	198.40	412.25	1,995.18	1,649.44	2,027.77
II Other Income	30.43	30.29	-	97.58	-	105.63
III Total Income (I+II)	1,471.60	228.69	412.25	2,092.76	1,649.44	2,133.40
IV Expenses						
(a) Cost of materials consumed	1,375.91	191.86	397.50	1,911.65	1,590.41	2,003.13
(b) Purchases of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefit expense	6.23	1.17	3.18	8.51	10.71	18.43
(e) Finance Costs	-	-	-	-	-	-
(f) Depreciation and amortisation expense	-	-	-	-	-	0.06
(g) Other Expenses	12.29	3.31	2.89	39.31	17.18	26.29
Total expenses (IV)	1,394.43	196.35	403.56	1,959.47	1,618.30	2,047.91
V Profit/(loss) before exceptional items and tax (III-IV)	77.17	32.34	8.69	133.29	31.14	85.49
VI Exceptional items	-	-	-	-	-	-
VII Profit (loss) after exceptional items and before Tax (V-VI)	77.17	32.34	8.69	133.29	31.14	85.49
VIII Tax Expense	-	-	-	-	-	23.42
(a) Current Tax	-	-	-	-	-	23.42
(b) (Less)- MAT Credit	-	-	-	-	-	-
(c) Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(d) Deferred Tax (Asset)/Liabilities	-	-	-	-	-	-
IX Profit (Loss) after Tax for the period (VII-VIII)	77.17	32.34	8.69	133.29	31.14	62.07
X Other Comprehensive Income						
a. i. Items that will not be reclassified to profit or loss	-	-	-	-	-	-
ii. Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
b. i. Item that will be reclassified to profit or loss	-	-	-	-	-	-
ii. Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive income	-	-	-	-	-	-
XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	77.17	32.34	8.69	133.29	31.14	62.07
XII Details of equity share capital						
Paid-up equity share capital	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24
Face value of equity share capital (Per Share)	1.00	1.00	1.00	1.00	1.00	1.00
XIII Other Equity	-	-	-	-	-	2,311.51
XIV Earnings per share						
(a) Earnings per share (not annualised for quarter ended)						
Basic earnings (loss) per share from continuing operation	0.02	0.01	0.00	0.03	0.01	0.02
Diluted earnings (loss) per share from continuing operation	0.02	0.01	0.00	0.03	0.01	0.02

Notes on Financial Results:-

- 1 The above unaudited standalone financial results for the quarter ended December 31, 2024 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on February 04, 2025. The statutory auditors have carried out limited review of above result.
- 2 The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
- 3 As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment.
- 4 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
- 6 Provision for Taxation if any will be made at year end.

For, Shree Ganesh Biotech (India) Limited

Date :- 04th February, 2025
Place:- Kolkata


Aman Patel
 Wholtime Director
 DIN: 08383544



Limited Review Report

To
The Board of Directors of
SHREE GANESH BIO-TECH (INDIA) LIMITED
KOLKATA


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SHREE GANESH BIO-TECH (INDIA) LIMITED** ("the Company"), for the Quarter ended on December 31, 2024 and year to date result for the period from 01 April, 2024 to 31 December, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah
Partner
M. No.: 126337
UDIN : 25126337BMLIBY3277
Place: Vadodara
Date: 04/02/2025



SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016

Email: shreeganeshbiotechindia@gmail.com Website: www.shreeganeshbiotech.com

Date: 04.02.2025

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange
of India Limited
Vibgyor Towers, 4th floor, Plot
No C 62, Opp. Trident Hotel
Bandra Kurla Complex, Bandra
(E),
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREGANES

Dear Sir/Madam,

Sub: Disclosure under Regulation 32(1) of SEBI (listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to SEBI Circular - CIR/CFD/CMD1/162/2019 dated 24th December, 2019 regarding statement on Deviation or variation for proceeds of public issue/Rights Issue/preferential issue, Qualified institutional placement (QIP) etc., read with Regulation 32(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform that:

The Company does not have any funds remaining unutilised as on 31st December 2024, or as on date, out of the proceeds of public issue/Rights Issue/preferential issue, qualified institutional placement (QIP) etc., if any undertaken by it at anytime in the past.


In view of the aforesaid, no information is being provided by way of Annexure-A pursuant to the said Regulation / Circular.

This is for your information and records.

Thanking You.

Yours faithfully

FOR, SHREE GANESH BIOTECH (INDIA) LIMITED


Aman Patel
Wholletime Director

